Related by context. All words. (Click for frequent words.) 69 EURIDIS 67 CALGB 66 CLARITY TIMI 66 Edge STudy 66 Multicenter Phase 66 HYVET 65 Clinical Antipsychotic Trials 65 CHAMPION PCI 65 Endovascular Valve Edge 65 Prospective Randomized 64 CALGB # [002] 64 Intervention Effectiveness 64 Unstable Angina 64 Multicenter Automatic Defibrillator Implantation 63 Aggressive Reduction 63 CAMMS# 63 Prostate AdenoCarcinoma Treatment 63 HCV SPRINT 63 BCIRG 63 placebo controlled Phase III 63 Carotid Revascularization Endarterectomy vs. 63 Randomized Phase II 63 Phase III AFFIRM 63 ENESTnd 63 CLARITY study 63 APEX AMI trial 63 MERLIN TIMI 63 LUMINATE 63 ACCORD Lipid 63 number NCT# ClinicalTrials.gov 63 Oral Fingolimod 63 ARCOXIA 62 bepotastine besilate nasal spray 62 Digital Mammographic Imaging 62 relapsed MM 62 Intervention Trial GAIT 62 multicenter placebo controlled 62 Raloxifene Evaluation MORE 62 Demonstrates Sustained 62 Pivotal Phase III 62 ExTRACT TIMI 62 BR.# 62 Investigator Initiated 62 Alzheimer Disease Cooperative 62 MEND CABG 62 COU AA 62 Refractory Angina 62 CARE HF 62 NSABP B 62 INSPIRE Trial Phase III 62 RECORD1 62 Therapeutic Arthritis 62 HORIZONS AMI 62 evaluating mipomersen 62 Teriflunomide 62 Intervention Trial 62 ACUITY trial 62 Phase Ib clinical 62 Phase III ThermoDox 62 AIR CF1 62 RE LY ® 62 Delcath Phase III 62 SORT OUT III 61 Acute Myocardial Infarction 61 CALERIE 61 STRIDE PD 61 Multicenter 61 Randomized Evaluation 61 Pooled Analysis 61 TRITON TIMI 61 blinded randomized placebo controlled 61 PARTNER Trial 61 HCV RESPOND 2 61 GOUT 61 recurrent glioblastoma multiforme 61 Cholesterol Levels SPARCL 61 CHARM Added 61 Intervention Effectiveness CATIE 61 REVIVE Diabetes 61 Wisconsin Sleep Cohort 61 Uterine Cancer 61 Patient Outcomes 61 Liraglutide Effect 61 Phase III multicenter 61 Myocardial Infarction Study 61 AIM HIGH 61 BZA CE 61 ThermoDox ® clinical 61 Prostate Lung Colorectal 61 multicenter multinational 61 CIMZIA TM certolizumab pegol 61 Lipid Lowering Treatment 61 First Patient Enrolled 61 Newly Diagnosed Multiple Myeloma 61 Acute Coronary Syndromes 61 SPIRIT FIRST 61 PRECiSE 61 BRIM3 60 AIR CF2 60 Glucosamine Chondroitin Arthritis 60 Ovarian PLCO Cancer 60 Screening Trial DMIST 60 Left Ventricular Dysfunction 60 Randomized Controlled 60 Successfully Completes Phase 60 Spine Patient Outcomes 60 AA Amyloidosis 60 Prostate Cancer Prevention 60 Prospective Multicenter 60 MADIT 60 Gastric Cancer 60 Severe Asthma 60 Phase Ib II 60 Phase III placebo controlled 60 EXPLORE Xa 60 Investigational Drug 60 Randomized Phase III 60 Celecoxib APC trial 60 randomized controlled multicenter 60 CATIE AD 60 Meets Primary Endpoint 60 Phase IIIb clinical 60 RE LY 60 APEX PD 60 Tanespimycin 60 ENDEAVOR IV 60 BRIM2 60 AVERROES 60 ONTARGET 60 multicentre randomized 60 FluCAM arm 60 prospective multicentre 60 Investigational Treatment 60 NEVO RES 60 TMC# C# 60 Hepatotoxicity 60 familial amyloidotic polyneuropathy FAP 60 IMPACT DCM 60 ASSERT 60 NO# [002] 59 linaclotide treated 59 Phase Ib IIa 59 Prolongs Survival 59 NATRECOR R 59 BARI 2D 59 ToGA 59 ug dose 59 ACRIN 59 ZACTIMA 59 HORIZONS AMI trial 59 ENDEAVOR III 59 TRA 2P 59 Controlled Trial 59 Val HeFT 59 ACR# ACR# 59 Relapsing Multiple Sclerosis 59 CLL8 59 Asthma Intervention 59 HCV Protease Inhibitor 59 Randomized Double Blind 59 Crit Rev 59 Acute Ischemic Stroke 59 Serious Adverse Events 59 R# #mg BID 59 Zemplar Capsules 59 PEGylated interferon beta 1a 59 Combination REOLYSIN R 59 Myelodysplastic Syndrome MDS 59 multicenter Phase III 59 Study Evaluating 59 Advaxis Phase 59 ICON7 59 MAGE A3 ASCI 59 dose escalation phase 59 elotuzumab 59 Initiates Phase III 59 Hsp# Inhibitor 59 Sorafenib HCC Assessment 59 Platelet Inhibition 59 ATACAND 59 severe hypercholesterolemia 59 EVEREST II 59 EchoCRT 59 REALITY Trial 59 MADIT II 59 Dialysis Outcomes 59 Non inferiority 59 APPRAISE 59 Randomized controlled 59 Multicentre 59 Hematological Cancers 59 multicentre prospective 59 phase IIIb 59 AVADO 59 SIMPADICO 59 See CLINICAL PHARMACOLOGY 59 multicenter randomized controlled 59 ROCKET AF 59 Tesmilifene 59 Phase 2b Clinical Trial 59 Gynecologic Oncology Group 59 LUX Lung 59 Ovarian Cancer Screening 59 TASKi2 59 Clinical Outcomes Utilizing Revascularization 59 Phase Ib Clinical Trial 59 Randomized Double blind 59 placebo controlled multicenter 59 Hormone Refractory Prostate Cancer 59 Randomized Phase 59 PEGINTRON REBETOL combination 58 relapsing multiple sclerosis 58 Preclinical Models 58 Daclizumab 58 ALN HPN 58 mITT population 58 GERD migraine headaches 58 Nesiritide 58 multicenter prospective 58 Subgroup Analysis 58 HER2 positive metastatic breast 58 WHEL 58 neratinib 58 Pivotal Phase 58 coinfected patients 58 Decompensated Heart Failure 58 Women Ischemia Syndrome 58 recurrent malignant glioma 58 placebo controlled clinical 58 Enzastaurin 58 ZOLINZA 58 TIMI Study Group 58 AACR IASLC Joint 58 placebo controlled Phase 58 Cardiotoxicity 58 DIRECT Trial 58 Trial Evaluating 58 AVOREN 58 Randomized Study 58 Inflammatory Markers 58 CYPHER Stent 58 Second Pivotal Phase 58 Neoadjuvant 58 Randomized Controlled Trials 58 R lenalidomide 58 Non Alcoholic Steatohepatitis 58 HDAC Inhibitor 58 multicenter randomized clinical 58 Hepsera adefovir dipivoxil 58 oral FTY# 58 Chemotherapeutic Agents 58 Primary endpoints 58 CONQUER OB 58 Brentuximab Vedotin SGN 58 HOPE TOO 58 NSABP 58 SPARCL 58 prospective observational studies 58 PRESEPT 58 Heterozygous Familial Hypercholesterolemia 58 CYT# potent vascular disrupting 58 Stent Thrombosis 58 galiximab 58 ST Segment Elevation 58 Completes Patient Enrollment 58 Adjuvant Chemotherapy 58 eritoran 58 PROactive study 58 OPT CHF 58 azilsartan medoxomil 58 Hematological 58 Investigational Compound 58 Renal Cell Carcinoma RCC 58 mcg albinterferon alfa 2b 58 PROactive Study 58 MGd 58 certolizumab 58 Survivorship Program 58 Prostate Disease 58 Eluting Stent 58 Heart Failure Patients 58 Initiate Phase 58 Evaluation WISE 58 Severe Sepsis 58 evaluating Actimmune 58 Velcade bortezomib 58 stage IIIb IV 58 Shows Efficacy 58 SCD HeFT 58 recurrent metastatic ovarian cancer 58 Aryplase 58 Canadian Multicentre Osteoporosis 58 PreCISe 58 RIO Lipids 58 Percutaneous Coronary Intervention 58 Coronary Artery Calcium 58 Study ADCS 58 Randomized Trials 58 PERSEUS 58 Clinical Trial Data 58 Patients Receiving 58 Ridaforolimus 58 Folfox 58 BEXXAR Therapeutic Regimen 58 VaD 58 ORAL Solo 58 Multicenter Randomized 57 ADMIRE HF 57 RE MODEL 57 ruboxistaurin 57 Sipuleucel T 57 SWOG 57 BOLDER II 57 fosbretabulin 57 Granted Orphan Drug 57 Hormone Receptor Positive 57 RIO Diabetes 57 Combination Treatment 57 multicenter Phase II 57 longitudinal observational study 57 Surgical Treatment 57 Pharmacokinetic 57 treatment naive genotype 57 EmbraceAC 57 Malignant Glioma 57 Demonstrates Efficacy 57 Screening Trial 57 VADT 57 Venous Thromboembolism 57 Chicago Multidisciplinary Symposium 57 Antihypertensive 57 Hypertensive adverse reactions 57 heavily pretreated 57 mg BID dose 57 randomized Phase IIb 57 Initiates Phase 2b 57 riociguat 57 Reduce Cardiovascular 57 Golimumab 57 Long Term Efficacy 57 Recurrent Glioblastoma 57 landmark ATHENA 57 ARCALYST ® rilonacept 57 somatostatin analog 57 FIX HF 5 57 Initiates Phase II 57 Coronary Artery Bypass Graft 57 GENASIS 57 ritonavir boosted 57 VICTOR E3 57 By JENNIFER LEARN 57 CANCIDAS 57 Phase 2b Trial 57 ENGAGE AF TIMI 57 comparator arm 57 Reduces Mortality 57 recurrent glioma 57 Septic Shock 57 Chronic Heart Failure 57 subanalysis 57 Echocardiographic 57 Temsirolimus 57 placebo controlled clinical trials 57 sorafenib Nexavar 57 prospective observational cohort 57 PLCO 57 IMPACT IMmunotherapy 57 AIR2 Trial 57 Phase #/#a 57 MEND CABG II 57 GISSI 57 Arch Neurol 57 Phase III HEAT 57 Renal Cancer 57 LibiGel Phase III 57 ACCOMPLISH 57 prucalopride 57 Multi Ethnic Study 57 venlafaxine Effexor 57 prelicensure 57 REMINYL ® 57 Infarct 57 oral ridaforolimus 57 Antiplatelet Therapy 57 cisplatin gemcitabine 57 Drug Prevents 57 EDEMA3 57 Stenting Trial CREST 57 Hepatitis C Antiviral 57 refractory CLL 57 Atherosclerosis MESA 57 MEK Inhibitor 57 National Emphysema Treatment 57 MADIT CRT 57 Patient Registry 57 ASCEND HF 57 GISSI HF 57 Candesartan 57 KRN# 57 ONTARGET R 57 ABCSG 57 Carotid Endarterectomy 57 Ischemic 57 Clinical Outcome 57 Ocular Hypertension Treatment 57 Vildagliptin 57 FOLPI 57 Commences Phase III 57 sorafenib tablets 57 FOLOTYN ® 57 Raloxifene STAR 57 Observational Study 57 Renal Cell Carcinoma 57 TAXUS ATLAS 57 dosing cohorts 57 Aflibercept 57 Ranolazine 57 Adrenomyeloneuropathy AMN 57 XIENCE V PROMUS Stent 57 Vicriviroc 57 Adenoma Prevention 57 Hepatocellular Carcinoma 57 dirucotide MBP# 57 multicenter randomized Phase 57 Tarceva TM 57 Prednisone Against Refractory 57 Diabetes ACCORD 57 rFVIIa 57 interferon gamma 1b 57 sunitinib malate 57 Phase III Psoriasis 57 prospective observational 57 IMiDs ® compound 57 Phase 1a clinical 57 SPIRIT III 57 Radiation Therapy Oncology 57 Diamyd Medical Diamyd 57 atherothrombotic disease 57 PREZISTA r arm 56 postmenopausal osteoporotic women 56 Swedish Mammography Cohort 56 evaluating tivozanib 56 retrospective cohort 56 immunomodulatory agents 56 pegylated interferon alfa 2b 56 Clinical Trial Results 56 phase IIb clinical 56 Shows Promise Against 56 evaluating satraplatin plus 56 Romidepsin 56 Teva Provides Update 56 PROSTVAC VF 56 CALGB # [001] 56 NCT# ClinicalTrials.gov 56 clinico pathological 56 Multiple Ascending Dose 56 Trandolapril 56 Prognostic Factors 56 Pulmonary Arterial Hypertension 56 NATRECOR ® 56 Tumor Response 56 huN# DM1 56 definite stent thrombosis 56 Heart Failure Trial 56 Renal Transplantation 56 randomized Phase III 56 prospectively defined 56 Abiraterone Acetate 56 relapsing remitting MS RRMS 56 Acute Decompensated Heart Failure 56 secondary efficacy endpoints 56 AVAiL 56 randomized multicenter Phase III 56 Meta analyzes 56 HIV HCV coinfected 56 ACTIVE W 56 Cloretazine 56 multicenter clinical 56 phase Ib 56 observational cohort 56 Active Ulcerative Colitis 56 Relapsing Remitting Multiple Sclerosis 56 registrational Phase 56 canakinumab 56 Phase III psoriasis 56 Fibrillex TM 56 Recurrent Stroke 56 Bucindolol 56 Patients Treated With 56 Ophena TM 56 underwent CABG 56 HBeAg negative patients 56 Arch Intern Med 56 Fibromyalgia Syndrome 56 ARIXTRA 56 ELOXATIN 56 Diabetic Macular Edema 56 PRoFESS 56 Gemzar ® 56 decompensated liver disease 56 metastatic castration resistant 56 CIMZIA ™ 56 FDA defined valvulopathy 56 Multicenter AIDS 56 Arimidex Tamoxifen Alone 56 Phase 2b kidney transplant 56 polyarticular 56 Cardiovascular Risk 56 daily Infergen 56 viral kinetic 56 antiretroviral naïve 56 regorafenib 56 ALLHAT 56 SPIRIT IV 56 prospective nonrandomized 56 Amrubicin 56 Carotid Stenting 56 CAPACITY trials 56 TEAEs 56 acute PAO 56 Systematic Review 56 Doxil ® 56 Phase 1b clinical trials 56 intravenous RSD# 56 NCCTG N# 56 vismodegib 56 Initiates Clinical Trial 56 TRANSFORMS 56 afatinib 56 Health Initiative Observational 56 arterial thromboembolic events 56 rheumatoid arthritis psoriatic arthritis 56 visceral metastases 56 #-# Full Text 56 epoetin alpha 56 dyslipidemia hypertension diabetes 56 phase IIb trial 56 TAXUS IV 56 unfractionated heparin UFH 56 Diabetic Neuropathy 56 Western Airborne Contaminants 56 Double Blind Placebo 56 Picoplatin Efficacy After 56 subgroup analyzes 56 Osteoporotic Fractures 56 Cancer Incidence Mortality 56 Medullary Thyroid Cancer 56 Thrombolysis 56 ® adefovir dipivoxil 56 Lancet Oncology journal 56 Phase IIIb study 56 evaluating satraplatin 56 phase IIa clinical 56 Rosuvastatin 56 Neuroendocrine Tumors 56 Psoriasis Drug 56 Pemetrexed 56 HPTN 56 Cancer Incidence 56 SPRYCEL ® 56 Group RTOG 56 conducted retrospective cohort 56 TG MV 56 papillary renal cell carcinoma 56 Pivotal Trial 56 Inflammatory Diseases 56 refractory colorectal cancer 56 substudy 56 headache nasopharyngitis 56 Pharmacokinetic parameters 56 CLINICAL PHARMACOLOGY 56 multicenter randomized double 56 BioNumerik 56 novel oral anticoagulant 56 prospective randomized multicenter 56 Metabolic Disorder 56 AML MDS 56 Liprotamase 56 Vidaza ® 56 ascending dose 56 Symptom Management 56 CINQUIL 56 YONDELIS 56 Apixaban 56 longitudinal cohort study 56 NSABP C 56 ECASS 56 fluvastatin 56 morphometric vertebral fractures 56 Secondary efficacy endpoints 56 Pharmacodynamic 56 Arch Surg 56 relapsed myeloma 56 double blinded randomized 56 Insulin Resistance Atherosclerosis 56 Immunotherapeutic 56 APTIVUS r 56 Rilonacept 56 Meta Analysis 56 PCI ExTRACT TIMI 55 observational cohort study 55 Acute Coronary Syndromes ACS 55 Demonstrates Positive 55 atypical Hemolytic Uremic Syndrome 55 tramiprosate Alzhemed TM 55 Drug Shows Promise 55 phase III isavuconazole 55 HeFT 55 Laryngeal Cancer 55 lexidronam injection 55 5 Fluorouracil 55 Proellex TM 55 CUSTOM III 55 Clinicaltrials.gov 55 ipsilateral breast 55 venlafaxine XR 55 NCIC CTG 55 ENDEAVOR IV clinical 55 CABG Surgery 55 Initiates Enrollment 55 ongoing Phase 1b 55 Polyp Prevention Trial 55 multicentre randomized controlled 55 Forodesine HCl 55 GSK# [001] 55 HeFH 55 Randomised 55 Complications Trial 55 REACH Registry 55 CombAT 55 Phase 1b clinical 55 Deforolimus 55 rALLy clinical trial 55 psoriatic arthritis PsA 55 PIX# [002] 55 intravesical infusion therapy 55 Coronary Revascularization 55 CAMMS# Phase 2 55 Cardiovascular Outcomes 55 oxycodone CR 55 Phase IIIb 55 Kidney Int 55 Novel Oral 55 rALLy 55 ASCO Breast Cancer 55 ACCORD Eye 55 Dementia Related Psychosis 55 Nonalcoholic Fatty Liver Disease 55 REVIVE TA 55 DAPT 55 PERSEUS clinical program 55 Placebo controlled 55 investigational protease inhibitor 55 randomized controlled Phase 55 prospectively stratified 55 Degarelix 55 phase III ACCLAIM 55 Medidur TM FA 55 Pegylated Interferon 55 Cardiometabolic 55 Lung Cancer Drug 55 unresectable malignant mesothelioma UMM 55 Outpatient Setting 55 CARDIA 55 Long Lesion 55 Phase III randomized 55 Leukemias 55 Acute Liver Failure 55 Myocardial Infarction 55 Hodgkin lymphoma HL 55 evaluable subjects 55 Bronchiectasis 55 J Am Coll 55 ENDEAVOR II 55 APTIVUS 55 FOLFOX6 chemotherapy regimen 55 phase IIa 55 dalteparin 55 DEB# 55 Genes Predict 55 Triapine 55 Geodon ziprasidone 55 mg administered orally 55 Advanced Renal Cell 55 Presents Positive 55 Bayer HealthCare Onyx Pharmaceuticals 55 RCW breast cancer 55 Prostate Cancer Patients 55 Phase IIb III 55 Chronic Myeloid Leukemia 55 invasive aspergillosis 55 Biomarker Study 55 Follicular Lymphoma 55 phase IIb study 55 Preclinical Study 55 standard chemotherapy regimen 55 iPrEx 55 bazedoxifene conjugated estrogens 55 evaluating Xcytrin 55 Vaccine Protects Against 55 multicenter randomized Phase III 55 TASKi3 55 ALSYMPCA 55 GVAX Pancreas Vaccine 55 acyclovir Lauriad R 55 TDF FTC 55 cancer mCRC 55 pharmacokinetic PK 55 recurrent NSCLC 55 Lung Cancer Trial 55 oral rivaroxaban 55 ACZ# 55 Alpha Tocopherol Beta Carotene 55 GATTEX TM 55 stage IIIB 55 Solid Tumors 55 Phase 2a Trial 55 ACOSOG Z# 55 Perifosine KRX 55 aldosterone antagonist 55 heFH 55 DAPT Study 55 TAXUS VI 55 PRIMO CABG 55 pharmacodynamic profiles 55 aspirin clopidogrel 55 abiraterone acetate 55 ORACLE MS 55 randomized controlled clinical 55 Acute Renal Failure 55 nucleoside naive 55 thromboembolic complications 55 Autologous Stem Cell Transplantation 55 Acute Exacerbations 55 Juvenile Idiopathic Arthritis 55 Non Alcoholic Fatty 55 Sleep Disturbances 55 nonmetastatic 55 active comparator 55 Morbidity Mortality 55 malignant mesothelioma Alfacell 55 Malignant Melanoma 55 CUSTOM II 55 hormone refractory metastatic prostate 55 Phase III Clinical Trial 55 J Clin Endocrinol Metab 55 neoadjuvant treatment 55 RTOG 55 Depression Study TADS 55 Completes Enrollment 55 Femara letrozole 55 essential thrombocythemia ET 55 COPERNICUS 55 pharmacogenomic translational research 55 Multicenter Study 55 SABCS 55 brivaracetam 55 ORAL Sync 55 RELOVAIR ™ 55 multicenter phase 55 J Nutr 55 Metastatic Melanoma 55 Gentium Announces 55 IMiDs ® 55 CIMZIA TM 55 Renal dysfunction 55 mitoxantrone plus 55 Pafuramidine 55 pertuzumab 55 J Clin Oncol 55 Ischemic Stroke 55 Fulvestrant 55 Hepatitis C Virus 55 Cervical Dysplasia 55 quadrivalent HPV vaccine 55 ximelagatran 55 invasive candidiasis 55 cardio renal 55 ritonavir boosted atazanavir 55 MELD scores 55 #mg QD [002] 55 Localized Prostate Cancer 54 Targretin capsules 54 confirmatory clinical 54 multicenter randomized placebo controlled 54 HBeAg negative 54 Drug Fails 54 GetGoal Phase III 54 Childhood Asthma 54 Aortic Stenosis 54 cyclophosphamide FC 54 null responder HCV 54 axitinib 54 p# biomarker 54 GI motility disorders 54 GW# [003] 54 Aliskiren 54 Atorvastatin Evaluation 54 AVN# Phase 54 Stenting Trial 54 branch RVO 54 Antitumor Activity 54 randomized multicenter trial 54 Charles Dullin School 54 #:#-# [031] 54 Trial PCPT 54 controlled multicenter Phase 54 SUTENT ® 54 HDL Selective Delipidation 54 Mycophenolate Mofetil 54 Common Toxicity Criteria 54 echinacea tablets 54 multicenter trials 54 Pegylated Liposomal Doxorubicin 54 ANCHOR trial 54 Teplizumab 54 Phase #b/#a clinical 54 HF ACTION 54 Neuroepidemiology 54 FOLFOX4 54 prospective longitudinal 54 Clinical Efficacy 54 Observational Studies 54 ISEL 54 Clostridium difficile Infection 54 Arthritis Rheum 54 SPEAR Study 54 kidney urologic 54 targeting miR 54 PROPEL 54 trastuzumab Herceptin R 54 EMPHASIS HF trial 54 dose escalation clinical 54 Fixed Dose 54 prospective multicenter randomized 54 Malignancies 54 UPLYSO 54 de novo kidney transplant 54 Cohort Consortium 54 Lymphocytic 54 alvespimycin 54 efavirenz EFV 54 Sequenced Treatment Alternatives 54 PREVENT IV 54 Double Blind Randomized 54 Glucosamine chondroitin Arthritis 54 orally inhaled migraine 54 receptor tyrosine kinase inhibitor 54 Postdoctoral Position 54 serotonin norepinephrine reuptake inhibitor 54 Eluting 54 beta 1a 54 midstage clinical 54 pralatrexate injection folate analogue 54 Abstract Accepted 54 acute coronary syndromes ACS 54 ADONIS 54 MSI #F 54 Practice Patterns 54 Fabry Disease 54 Initiates Clinical 54 nonrandomized 54 Home Buyer Seller 54 CR# vcMMAE 54 sapacitabine CYC# 54 HQK 54 antiretroviral naive 54 Bivalirudin 54 Initiated Phase 54 Antisoma AS# 54 dimebon latrepirdine 54 DCCT EDIC 54 CYPHER R stent 54 ERSPC 54 Clinical Psychopharmacology 54 Subgroup analysis 54 tarenflurbil 54 Nord Trøndelag Health 54 elevated ALT 54 tenofovir emtricitabine 54 EQUIP OB 54 ISTODAX ® 54 Critical Limb Ischemia CLI 54 Multiple Myeloma Patients 54 FASEB J. 54 MKC# MT 54 ALT flares 54 OvaRex ® MAb 54 paroxetine Paxil 54 Pharmacologic 54 lorcaserin Phase 54 ezetimibe simvastatin 54 Phase III Clinical Trials 54 circulating endothelial cells 54 placebo controlled studies 54 Uterine Fibroid Embolization 54 ATTAIN 54 Recurrent Breast Cancer 54 Judith Hochman 54 M# rationally 54 Pivotal Clinical Trial 54 MADIT CRT trial 54 IMiDs R 54 Orphan Diseases 54 ABSORB trial 54 Roche Boniva 54 thiazolidinediones TZDs 54 Randomized Clinical Trials 54 Androxal TM 54 Vaccine Adjuvant 54 Placebo Controlled 54 meta regression 54 Eye Diseases 54 IMPROVE HF 54 TACI Ig 54 carbamazepine phenobarbital phenytoin rifampin 54 #I TM# 54 hypercholesterolemic patients 54 Maven Semantic 54 ENLIGHT 54 HBV infections 54 Sociodemographic 54 experimental antibiotic Trovan 54 multicenter randomized 54 cilostazol 54 Oncophage vaccination 54 RhuDex 54 TNF antagonist 54 PF # [002] 54 Valsartan 54 olaparib 54 Detection Evaluation 54 Phase 1b trial 54 phase IIb 54 blinded randomized controlled 54 ADVANCE PD 54 chronic myocardial ischemia 54 orally administered inhibitor 54 Relieve Depression 54 Kaplan Meier estimates 54 Paroxysmal Nocturnal Hemoglobinuria PNH 54 Pharmacokinetics PK 54 tolerability pharmacokinetics 54 Ann Oncol 54 Schizophrenia Bulletin 54 angiotensin converting enzyme inhibitors 54 Vitrasert R 54 compound INCB# 54 Unresectable 54 randomized Phase 2b 54 myocardial infarctions 54 Phase III VISTA 54 hyperphenylalaninemia HPA due 54 ASTEROID 54 echocardiographic parameters 54 beta carotene supplementation 54 FAME Study 54 T1c 54 Xelox 54 Phase IIA 54 multicenter Phase 54 Sherlock uncovering 54 liver transplant recipients 54 HNRCA 54 Bankruptcies soar 54 RE LY trial 54 HMG CoA reductase inhibitors 54 Faropenem 54 ARBITER 6 53 Prevent Stroke 53 hepatitis C genotype 53 GAMMAGARD 53 Chronic Hepatitis C 53 prospective randomized placebo 53 Gynecological Cancer 53 squamous histology 53 Prospective Randomized Double 53 Cancer Prevention ATBC 53 GSK# [002] 53 Truvada tablets 53 tolvaptan 53 K ras mutations 53 Young Adults CARDIA 53 placebo controlled dose escalation 53 placebo controlled trials 53 lipid lowering agents 53 receiving SIMPONI 53 MIST II 53 NYHA Class II 53 Hospitalized Patients 53 paclitaxel eluting stents 53 COSTAR II 53 Biological Therapy 53 Fondaparinux 53 Study ARIC 53 Oral Insulin Capsule 53 demonstrated antitumor activity 53 budesonide foam 53 nucleotide analogue